Your browser doesn't support javascript.
loading
Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
Olah, Csilla; Kubik, András; Mátrai, Péter; Engh, Marie Anne; Barna, Viktória; Hegyi, Péter; Reis, Henning; Nyirády, Péter; Szarvas, Tibor.
Affiliation
  • Olah C; Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK), Essen, Germany.
  • Kubik A; Department of Urology, Semmelweis University, Budapest, Hungary; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Mátrai P; Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Engh MA; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Barna V; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Hegyi P; Centre for Translational Medicine, Semmelweis University, Budapest, Hungary; Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.
  • Reis H; Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Nyirády P; Department of Urology, Semmelweis University, Budapest, Hungary.
  • Szarvas T; Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK), Essen, Germany; Department of Urology, Semmelweis University, Budapest, Hungary. Electronic address: szarvas.tibor@semmelweis.hu.
Urol Oncol ; 42(7): 221.e1-221.e7, 2024 Jul.
Article de En | MEDLINE | ID: mdl-38627107
ABSTRACT

BACKGROUND:

Urachal cancer (UrC) is a rare disease with limited availability of representative incidence and clinical data. Although, the prevalence is accounting for less than 1% of bladder tumors, the 5-year survival rate is around only 50% for patients with resectable tumors, and even worse for patients with metastatic disease. Due to the lack of comprehensive prospective studies, our current knowledge of UrC is still limited.

OBJECTIVE:

The present study aimed to summarize the available registry-based studies with unselected UrC patients to evaluate its incidence and clinicopathological characteristics. MATERIAL AND

METHODS:

We conducted a systematic literature search of registry-based UrC publications on the 15th of May 2023 in 5 databases, which identified 4,748 publications. After duplicate removal and selection by 2 independent investigators, 6 publications proved to be appropriate for the final meta-analysis. Estimated incidence and clinicopathological parameters were extracted.

RESULTS:

Estimated incidence ranged between 0.022 and 0.060/ 100.000 person-years, with the highest occurrence in Japan and the lowest in Canada, while the random effect model calculated an overall incidence rate of 0.04 (95%CI 0.03-0.05) 100.000 person-years. The median age at first diagnosis was 60 years (range 58-64). The female to male ratio was 23. Lymph node or distant metastases were present in 9% and 14% of patients. The predominant tumour type was adenocarcinoma (86%) followed by urothelial carcinoma (12%) and squamous cell carcinoma (2%). The 5-year survival rate was 51.0% with 95%CI 45.2-57.4.

CONCLUSIONS:

Our study provides an up-to-date comparison of estimated incidence rates between 6 countries of 3 continents based on rigorously selected registry-based studies. The results suggest low incidence rates for UrC with considerable geographic differences. The present meta-analysis provides unbiased registry-based data on the incidence, clinicopathological parameters and survival of UrC.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la vessie urinaire / Enregistrements Limites: Humans / Male Langue: En Journal: Urol Oncol Sujet du journal: NEOPLASIAS / UROLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la vessie urinaire / Enregistrements Limites: Humans / Male Langue: En Journal: Urol Oncol Sujet du journal: NEOPLASIAS / UROLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: États-Unis d'Amérique